Browse studies

Find your next paid study

103 recruiting studies matching your filters

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (C…

Lung Cancer (Diagnosis)OsteochondromaSpitz Nevus+14 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT07675967

Phase 1

A Phase 1 Study of AWT020 in Patients With Advanced Solid Tumors

This study is aimed at establishing the MTD and/or the RP2D for AWT020 monotherapy and to provide safety, tolerability, efficacy, PK, immunogenicity characteri…

Advanced Cancers (Solid Tumors)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Anwita BiosciencesNCT07822919

Phase 1

CATALINA-4: Phase 1B/2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer

A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Canc…

FIGO Stage III and IV Ovarian CancerFallopian Tube CancersPrimary Peritoneal Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

TORL Biotherapeutics, LLCNCT07322094

Phase 1

A First-in-Human, Open-label, Multicenter, Phase 1 Study of EPI-326 in Patients With Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with …

Epidermal Growth FactorEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Gene Mutation+12 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Phase 2

Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.

The goal of clinical trial is to test an FDA approved drug called Pafolacianine that attaches to cancer cells and lights up when seen through a special camera …

Esophageal CancerGastrointestinal CancersGynecologic Cancers

Estimated

~$75 – $3,000

Actual pay is set by the research site.

John WatersNCT07039526

Observational

Evaluating Optimal Perioperative Pain Management: A Prospective Randomized Control Trial of Laparoscopic Transversus Abdominis Plane Block With Local Anesthetic, Laparoscopic Transversus Abdominis Plane Block Alone, and Local Anesthetic Alone in Minimally Invasive Oncologic Surgery

This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally inv…

Oncologic SurgeryCancerCancer Surgery+8 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

An Observational Multi-Center Study to Evaluate Real-World Treatment Outcomes With or Without Durvalumab-Based Regimens in Hepatobiliary Cancers

Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemp…

Hepatobiliary Cancers

Estimated

~$10 – $1,125

Actual pay is set by the research site.

AstraZenecaNCT06252753

Data Collection Study of Pediatric and Adolescent Gynecology Conditions

Background: Gynecologic conditions are those that are related to the reproductive system. They can be reproductive gland disorders or reproductive system tumo…

Disorders of Sex Development (DSD)Pediatric and Adolescent Cancers of the Genital TractReproductive Endocrine Conditions in Puberty+1 more

Estimated

~$10 – $675

Actual pay is set by the research site.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT04717349

Phase 2

A Phase 2/3, Multicenter, Open-Label, Non-Randomized Study to Evaluate Diagnostic Performance of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) for Detection of Peritoneal Carcinomatosis (PC) in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in pat…

Colorectal CancerGastric CancersOvarian Cancers+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

GE HealthcareNCT07219238

Observational

A Phase II Study of Treatment De-Escalation for Favorable Prognosis, Stage I-II Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy

The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Re…

Oropharyngeal CancersHPVTonsil Cancer+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Georgetown UniversityNCT06902623

Phase 1

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effe…

Advanced Solid Cancers

Estimated

~$150 – $4,500

Actual pay is set by the research site.

BioNTech SENCT07186842

Observational

Comparative Study on Enhancing Oral Cancer Awareness: Classical Educational Materials vs. AI-Powered Chatbot

To evaluate the impact of AI-powered chatbot interactions versus traditional educational handouts on increasing participants' knowledge of oral cancer and its …

Oral CancerChatbotPatient Education+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Virginia Commonwealth UniversityNCT06682494